Pharma Industry Growth Slower In China, But Smaller Cities Still Growing
This article was originally published in The Pink Sheet Daily
Executive Summary
China’s pharmaceutical industry slowed last year, especially domestic companies, according to IMS. But MNCs also saw slower growth from price cuts.
You may also be interested in...
China's Changing Reimbursement Landscape Reshapes Pharma Market
SHANGHAI - China's prescription drugs market has seen a slowdown in growth in large cities due to implementation of government pilot reimbursement projects that could be adopted nationwide, according to a Sept. 27 Citi report
Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?
SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts